| Title |
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
|
|---|---|
| Published in |
OncoTargets and therapy, September 2016
|
| DOI | 10.2147/ott.s100515 |
| Pubmed ID | |
| Authors |
Sameem M Abedin, Craig S Boddy, Hidayatullah G Munshi |
| Abstract |
The bromodomain and extra-terminal (BET) family of proteins are important epigenetic regulators involved in promoting gene expression of critical oncogenes. BET inhibitors have been demonstrated to repress c-Myc expression, and were initially shown to have efficacy in a number of c-Myc-dependent hematologic malignancies. Recent studies have now revealed a broader role for BET inhibitors in hematologic malignancies. In this review, we summarize the efficacy of BET inhibitors in preclinical models of acute leukemia, lymphoma, and multiple myeloma. We also summarize recent results of clinical trials utilizing BET inhibitors in hematologic malignancies, characterize potential resistance mechanisms to BET inhibitors, and discuss potential combination therapies with BET inhibitors in patients with hematologic malignancies. |
Mendeley readers
The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 82 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 16% |
| Student > Master | 11 | 13% |
| Researcher | 9 | 11% |
| Student > Bachelor | 7 | 9% |
| Student > Doctoral Student | 6 | 7% |
| Other | 14 | 17% |
| Unknown | 22 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 26 | 32% |
| Medicine and Dentistry | 15 | 18% |
| Agricultural and Biological Sciences | 10 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Chemistry | 2 | 2% |
| Other | 4 | 5% |
| Unknown | 23 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 February 2023.
All research outputs
#8,535,472
of 25,374,917 outputs
Outputs from OncoTargets and therapy
#547
of 3,016 outputs
Outputs of similar age
#124,892
of 348,376 outputs
Outputs of similar age from OncoTargets and therapy
#16
of 86 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,376 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 86 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.